Please assess the completion status of the following clinical trial:

Trial Title: Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants delivered at a gestational age of less than or equal to 35 6/7 weeks (Preterm) being treated with high velocity nasal insufflation therapy for the management of respiratory distress syndrome~2. Patients that clinically require SpO2 maintenance within the target range of 90-95%~3. A need for supplemental oxygen as demonstrated by a required FiO2 \> 0.25 at enrollment~4. Requiring a flow rate of greater than 2 L•min-1 such that the assumed inspired oxygen fraction matched delivered oxygen fraction (definition of HVNI).~5. A minimum of 6 manual FiO2 adjustments in the 24hr period prior to trial enrollment.~6. Willing/Able to complete informed consent.~Exclusion Criteria:~1. Current patient weight of \<1000g or \>3500g at time of study~2. Major congenital abnormalities~3. Hemodynamic instability, defined as being outside of a normotensive range based on an infant's individual characteristics by clinician~4. Persistent unresolved apnea defined as: requiring 6 stimulations or more per 6 hours~5. Seizures~6. Ongoing sepsis~7. Meningitis~8. Clinician's concern regarding stability of the infant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Automated Control (OAM) (Type: EXPERIMENTAL): In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
- Manual Control (Manual) (Type: ACTIVE_COMPARATOR): In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.

Based on this trial design, predict the completion outcome and termination type (if applicable).